Kailera Therapeutics, Inc.

Cosa ha dichiarato Kailera Therapeutics, Inc. il 12 agosto 2026

Dal 8-K dell’azienda.

Conference call sui risultati

Per Kailera Therapeutics, Inc. non è disponibile alcuna trascrizione di conference call sui risultati.

Cosa ha detto il management

“Our second quarter marked another period of strong execution across the Kailera portfolio. We advanced our global Phase 3 KaiNETIC program for ribupatide injection, completed enrollment in our U.S. Phase 2b high-dose ribupatide injection trial with data expected in mid-2027, and opened our ribupatide oral IND, with initiation of our global Phase 3 obesity program planned for the first half of 2027,”

Citato alla lettera dal comunicato, e mostrato solo quando il documento lo attribuisce a una persona con nome e cognome.

Come ha reagito il prezzo

I comunicati escono dopo la chiusura o prima dell’apertura, quindi il movimento è quello della seduta successiva.

Cosa fa Kailera Therapeutics, Inc.

Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA.

La descrizione dell’azienda stessa, come compare in calce al comunicato.